Voyager Therapeutics (VYGR) H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference summary

Conference highlights

• Over 20 companies presented at the fifth annual H.C. Wainwright Virtual Neuro Perspectives Conference, with a focus on neurology indications and novel CNS drug delivery methods.

• Sessions included panels and fireside chats covering depression, epilepsy, Alzheimer's disease, ALS, and more.

Pipeline and platform updates

• Four wholly owned and 13 partnered neurogenetic medicine programs are advancing, with the lead antibody targeting tau in Alzheimer's now in phase 1.

• Three additional gene therapies are on track for IND filings in 2025, enabled by the TRACER capsid discovery platform for broad CNS delivery.

• Partnerships with Neurocrine, Novartis, and Alexion have expanded, reflecting confidence in the platform.

• Over $400 million in cash provides runway into 2027, supporting multiple clinical inflection points.

Recent data and scientific advances

• At ASGCT, 12 presentations highlighted second-generation TRACER capsids with improved CNS delivery and reduced off-target effects.

• Achieved up to 98% transduction in key neuronal populations and robust knockdown of disease targets in preclinical models.

• Identified ALPL as the receptor mediating blood-brain barrier penetration, supporting cross-species and human translation.